Roth Capital resumed coverage on Moleculin Biotech
$MBRX
Biotechnology: Pharmaceutical Preparations
Health Care
Roth Capital resumed coverage of Moleculin Biotech with a rating of Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/9/2025 | $4.00 | Buy | H.C. Wainwright |
| 2/12/2025 | Buy → Hold | Maxim Group | |
| 7/18/2022 | $14.00 | Outperform | Oppenheimer |